Long-term follow-up for X-linked myotubular myopathy treatment
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This study checks on the long-term health of people who already received the gene therapy ASP2957 for X-linked myotubular myopathy. It helps doctors learn how safe and effective the treatment is over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male.
- You have X-linked myotubular myopathy.
- You were treated with the study drug ASP2957 in a previous clinical trial.
- You are no longer receiving the study treatment in that earlier trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called ASP2957 in young boys with X-linked myotubular myopathy who are dependent on a ventilator. The goal is to see if it can help improve their breathing and muscle strength.
This study looks at how the liver works in boys with a serious muscle condition called XLMTM. It checks whether their liver is healthy, which may help doctors better understand the condition and guide future treatments.
This study follows up on patients with type 1 spinal muscular atrophy (SMA) who already received the EXG001-307 gene therapy in a previous trial. The goal is to monitor their long-term health and safety over time.
This long-term follow-up study watches people who previously received the experimental gene therapy RGX-202 for Duchenne muscular dystrophy. It checks how patients are doing over time and does not involve any new treatment.
This study checks how people with Duchenne muscular dystrophy are doing long-term after receiving delandistrogene moxeparvovec (SRP-9001) in an earlier trial. It helps researchers understand the long-term safety and effects of that treatment.
This study follows participants who have already received the gene therapy LX2020 for a genetic heart condition called arrhythmogenic cardiomyopathy. It tracks their long-term safety and health outcomes, with no new treatment given.
Hear when a new X-Linked Myotubular Myopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.